Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

45.4K
Overview
45.4K
Cross-reactivity00:42

Cross-reactivity

31.5K
Overview
31.5K
Development of Immunocompetence01:22

Development of Immunocompetence

463
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
463

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing dengue vaccination strategies.

PLoS medicine·2026
Same author

Country-level perspectives and priorities to guide the development of Invasive non-Typhoidal Salmonella (iNTS) vaccines: Insights from seven countries.

PLoS neglected tropical diseases·2026
Same author

The invasive non-typhoidal Salmonella vaccine landscape: Innovations and challenges ahead.

Vaccine·2026
Same author

Global disparities in the introduction, scale-up, and effectiveness evaluation of COVID-19 vaccines.

Nature communications·2025
Same author

WHO preferred product characteristics for bivalent Salmonella Typhi/Paratyphi A vaccine for comprehensive protection against enteric fever- key considerations and research gaps.

Gates open research·2025
Same author

Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations.

Vaccine·2025
Same journal

Correction: Fukushima et al. Long-Term Immunogenicity of Rabies Pre-Exposure Prophylaxis in Japanese Adult Travelers: Comparison of Dosing Regimens. <i>Vaccines</i> 2025, <i>13</i>, 1169.

Vaccines·2026
Same journal

Access to Vaccines Among Asylum Seekers, Refugees, and Undocumented Migrants Across the Migratory Cycle in the European Union, European Economic Area, Switzerland and the United Kingdom: A Scoping Review.

Vaccines·2026
Same journal

Advances in Detection Methods for Human Respiratory Syncytial Virus Neutralizing Antibodies.

Vaccines·2026
Same journal

Insights from 25 Years of Measles and Measles-Rubella Vaccination Campaigns in the WHO African Region (2001-2025).

Vaccines·2026
Same journal

Post-Marketing Safety Surveillance of Influenza Vaccines in Anhui Province, China, 2016-2025.

Vaccines·2026
Same journal

Characteristics of Hypotonic-Hyporesponsive Episodes (HHEs) Following Childhood Vaccination: A 13-Year Analysis of Spontaneous Reports to the Dutch Pharmacovigilance Centre Lareb.

Vaccines·2026
See all related articles

Related Experiment Video

Updated: Sep 20, 2025

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection
06:00

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection

Published on: January 26, 2024

1.5K

Dengue Vaccine Development and Deployment into Routine Immunization.

Annelies Wilder-Smith1, Thomas Cherian1, Joachim Hombach1

  • 1World Health Organization, CH-1211 Geneva, Switzerland.

Vaccines
|May 28, 2025
PubMed
Summary
This summary is machine-generated.

Integrating dengue vaccines like TAK-003 into routine immunization is vital for high-burden regions. Strategies include school-based programs and community engagement to combat rising dengue cases.

Keywords:
CYD-TDVQdengaTAK-003Wolbachiaantibody-dependent enhancementdenguemRNA vaccinesschool-based programs

More Related Videos

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum
07:06

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum

Published on: April 10, 2018

8.9K
Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction
08:36

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Published on: November 1, 2018

32.1K

Related Experiment Videos

Last Updated: Sep 20, 2025

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection
06:00

Author Spotlight: Development of a Smartphone-Enhanced Paper-Based Device for Rapid Dengue NS1 Detection

Published on: January 26, 2024

1.5K
A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum
07:06

A Simple Flow Cytometry Based Assay to Determine In Vitro Antibody Dependent Enhancement of Dengue Virus Using Zika Virus Convalescent Serum

Published on: April 10, 2018

8.9K
Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction
08:36

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Published on: November 1, 2018

32.1K

Area of Science:

  • * Tropical Medicine
  • * Vaccinology
  • * Public Health

Background:

  • * Dengue fever is a growing global health concern, with limited vaccine implementation despite decades of research.
  • * Currently, only two dengue vaccines, CYD-TDV (Dengvaxia) and TAK-003 (Qdenga), are licensed.
  • * High dengue incidence necessitates effective vaccination strategies.

Purpose of the Study:

  • * To explore and outline strategies for integrating dengue vaccines into routine immunization programs.
  • * To assess the efficacy and safety considerations of available dengue vaccines, particularly TAK-003.
  • * To inform decision-making for vaccine introduction in high-burden areas.

Main Methods:

  • * Review of existing literature on dengue vaccines and implementation strategies.
  • * Analysis of efficacy data for TAK-003, including against virologically confirmed dengue and hospitalizations.
  • * Examination of World Health Organization (WHO) recommendations and concerns regarding vaccine-enhanced disease.

Main Results:

  • * TAK-003 shows 61% efficacy against confirmed dengue and 84% against hospitalizations, but carries risks for seronegative individuals.
  • * WHO recommends targeted introduction of TAK-003 in high-transmission settings without pre-screening.
  • * Post-introduction studies are ongoing to clarify long-term safety and effectiveness.

Conclusions:

  • * Optimizing the use of current dengue vaccines is critical for reducing disease burden.
  • * Effective rollout requires school-based programs, adolescent health integration, and community engagement.
  • * Combining vaccination with vector control is essential for immediate impact on dengue morbidity and mortality.